News FocusImmunology

Stalling Sepsis?

See allHide authors and affiliations

Science  31 Aug 2012:
Vol. 337, Issue 6098, pp. 1036
DOI: 10.1126/science.337.6098.1036

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

Dosing rodents with an antibody that sticks to complement protein C5a spares them from sepsis. Several companies have begun testing C5a inhibitors for diseases such as atherosclerosis, and targeting the same molecule could be therapeutic for sepsis patients. Researchers are desperate for good news about the condition. More than 40 clinical trials of sepsis treatments have already failed, and the only drug approved in the United States specifically for sepsis, activated protein C, has been withdrawn from the market because of new evidence it doesn't work.